Overview

Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients

Status:
Unknown status

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

There is no standard treatment in patients with renal cell carcinoma that was previously treated with VEGF targeted therapies and mTOR inhibitors.So investigators conducted a randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with Metastatic renal cell carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Beijing Cancer Hospital

Treatments:

Bevacizumab
Niacinamide
Sorafenib